Recent advances of molecular genetic characteristics of small cell lung cancer

doi:10.3969/j.issn.1007-3969.2014.08.013

Welcome to China Oncology,

China Oncology ›› 2014, Vol. 24 ›› Issue (8): 630-635.doi: 10.3969/j.issn.1007-3969.2014.08.013

Previous Articles Next Articles

Recent advances of molecular genetic characteristics of small cell lung cancer

LIU Di, FAN Min

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2014-08-30 Published:2014-11-07
Contact: FAN Min E-mail: fanming@fudan.edu.cn

Share article

Abstract

Abstract:

Small cell lung cancer (SCLC) is an aggressive malignancy with fairly poor prognosis. Innovative treatment based on improved understanding of the genetic alterations of SCLC is awaited. Recently, a number of potential targets or important oncogenic pathways have been identified by the next generation sequencing or other systematic genomic analysis in SCLC. In this review, we summarised the new findings of genetic characteristics in SCLC.

Key words: Small cell lung cancer, Genomic variation, Gene expression profiling, Oncogenic pathway

LIU Di, FAN Min. Recent advances of molecular genetic characteristics of small cell lung cancer[J]. China Oncology, 2014, 24(8): 630-635.

[1]	LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications [J]. China Oncology, 2024, 34(4): 368-379.
[2]	ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis [J]. China Oncology, 2023, 33(8): 776-781.
[3]	SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022 [J]. China Oncology, 2023, 33(3): 218-227.
[4]	HE Liyuan, WANG Yudong. Research progress of ALK kinase domain drug resistance mutation and its future countermeasures [J]. China Oncology, 2022, 32(8): 736-746.
[5]	HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634.
[6]	SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486.
[7]	YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498.
[8]	FU Yuanyuan, HOU Runping, FU Xiaolong. Research progress in predicting the risk of lymphatic or hematologic metastasis based on chest CT in early non-small cell lung cancer [J]. China Oncology, 2022, 32(4): 343-350.
[9]	ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761.
[10]	LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588.
[11]	YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang . The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province [J]. China Oncology, 2021, 31(7): 616-628.
[12]	XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer [J]. China Oncology, 2021, 31(7): 635-639.
[13]	YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying . Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(3): 203-211.
[14]	ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li . Advances in the treatment of BRAF V600-mutant non-small cell lung cancer [J]. China Oncology, 2021, 31(12): 1145-1152.
[15]	SHEN Yujia , FU Xiaolong . Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer [J]. China Oncology, 2021, 31(11): 1115-1125.

Recent advances of molecular genetic characteristics of small cell lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments